Is Novavax, the Latecomer Covid Vaccine, Worth the Wait?
People with special medical considerations are hoping the Novavax shot will bring fewer headaches, fevers, and less fatigue than have been reported by those taking mRNA vaccines.
FDA
141 - 160 of 474 Results
-
-
Doubts Abound About a New Alzheimer’s Blood Test
Quest Diagnostics is selling a blood test online to consumers. But results may not be reliable or easy to interpret. And it isn’t covered by insurance.
-
California Moves Ahead of the FDA in Banning Common Candy Additives
The legislation bans the use of four additives that are already prohibited in many other countries but remain in popular U.S. foods. Advocates say states need to act because the FDA has done little.
-
PrEP, a Key HIV Prevention Tool, Isn’t Reaching Black Women
New HIV infections occur disproportionately among Black women, but exclusionary marketing, fewer treatment options, and provider wariness have limited uptake of preexposure prophylaxis, or PrEP, drugs, which reduce the risk of contracting the virus.
-
Thousands Got Exactech Knee or Hip Replacements. Then, Patients Say, the Parts Began to Fail.
In a torrent of lawsuits, patients accuse Florida device maker Exactech of hiding knee and hip implant defects for years. The company denies the allegations.
By Fred Schulte Underinsured Is the New Uninsured
Episode 314The percentage of working-age adults with health insurance went up and the uninsured rate dropped last year, the U.S. Census Bureau reported this week. There isn’t much suspense about which way the uninsured rate is now trending, as states continue efforts to strip ineligible beneficiaries from their Medicaid rolls. But is the focus on the uninsured obscuring the struggles of the underinsured? Margot Sanger-Katz of The New York Times, Sarah Karlin-Smith of the Pink Sheet, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News’ Emmarie Huetteman to discuss these issues and more.
-
Why the CDC Has Recommended New Covid Boosters for All
As covid-19 hospitalizations tick upward with fall approaching, the CDC says it’s time for new boosters — and not only for those at highest risk of serious disease. Here are seven things you need to know.
By Arthur Allen -
A Nanoengineer Teamed Up With Rihanna’s Tattoo Artist to Make Smarter Ink
Tattoos are more popular than ever. About a third of Americans have at least one. A scientist-entrepreneur, together with a celebrity tattoo artist, believes that ink could be doing a lot more.
-
Black Women Weigh Emerging Risks of ‘Creamy Crack’ Hair Straighteners
Social and economic pressures have long compelled Black girls and women to straighten their hair. But mounting evidence shows chemical straighteners — products with little regulatory oversight — may pose cancer and other health risks.
By Ronnie Cohen -
FDA Head Robert Califf Battles Misinformation — Sometimes With Fuzzy Facts
FDA Commissioner Robert Califf has called misinformation one of the deadliest killers in the United States. As the FDA tries to fight that scourge, it sometimes stumbles.
By Darius Tahir -
Once the New Over-the-Counter Birth Control Pill Is Available, What About Cost and Coverage?
The Food and Drug Administration’s approval is viewed as groundbreaking, but many details still must be figured out.
The Long Road to Reining In Short-Term Plans
Episode 305President Biden made good on a campaign promise this week with a proposal that would limit short-term health insurance plans that boast low premiums but also few benefits. Meanwhile, the Supreme Court’s decision to outlaw affirmative action programs could set back efforts to diversify the nation’s medical workforce. Alice Miranda Ollstein of Politico, Amy Goldstein of the Washington Post, and Rachel Cohrs of Stat News join KFF Health News’ chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KFF Health News’ Bram Sable-Smith, who reported the latest KFF Health News-NPR “Bill of the Month” about how a hospital couldn’t track down a patient, but a debt collector could.
-
As Low-Nicotine Cigarettes Hit the Market, Anti-Smoking Groups Press for Wider Standard
The first FDA-authorized cigarettes with 95% less nicotine than traditional smokes will go on sale in California, Florida, and Texas starting in early July. Anti-smoking groups oppose greenlighting just one plant biotech’s products and instead urge federal regulators to set a low-nicotine standard for the entire industry.
By Don Thompson -
E-Cigs Are Still Flooding the US, Addicting Teens With Higher Nicotine Doses
The FDA, Justice Department, and White House have failed to act as vapes with kid-friendly flavors like cotton candy or gummy bears proliferate.
By Liz Szabo -
Drugmakers Are Abandoning Cheap Generics, and Now US Cancer Patients Can’t Get Meds
A quality-control crisis at an Indian pharmaceutical factory has left doctors and their patients with impossible choices as cheap, effective, generic cancer drugs go out of stock.
By Arthur Allen -
How the Mixed Messaging of Vaccine Skeptics Sows Seeds of Doubt
Some GOP members of the House Select Subcommittee on the Coronavirus Pandemic have two-stepped around vaccine skepticism, proclaiming themselves to be pro-vaccine while also validating the beliefs of people who oppose vaccine mandates. The result could have serious public health consequences.
By Darius Tahir -
Mood-Altering Mushroom Sales Bloom Despite Safety Concerns
The well-known “Amanita muscaria” mushroom is legal to possess and consume in 49 states. The market for gummies, powders, and capsules containing extracts of the fungus is raising eyebrows, though, amid concerns from the FDA and in the absence of human clinical trials.
-
Watch: 5th Circuit Judges Question Two-Decade-Old Approval of Abortion Pill
The 5th Circuit Court of Appeals in New Orleans heard oral arguments Wednesday in a case brought by conservative Christian abortion opponents seeking to revoke FDA approval of mifepristone, a medication used in more than half of abortions in the U.S.
By Sarah Varney The Crisis Is Officially Ending, but Covid Confusion Lives On
Episode 297The public health emergency declaration for covid-19 ends May 11, ushering in major changes in how Americans can access and pay for the vaccines, treatments, and tests particular to the culprit coronavirus. But not everyone will experience the same changes, creating a confusing patchwork of coverage — not unlike health coverage for other diseases. Meanwhile, outside advisers to the FDA formally recommended allowing a birth control pill to be sold without a prescription. If the FDA follows the recommendation, it would represent the first over-the-counter form of hormonal contraception. Margot Sanger-Katz of The New York Times, Tami Luhby of CNN, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News’ Julie Rovner to discuss these issues and more. Plus for “extra credit” the panelists suggest health policy stories they read this week they think you should read, too.
-
Legal Pot Is More Potent Than Ever — And Still Largely Unregulated
As marijuana has become far more mainstream, potent, and sometimes dangerous, uneven regulation at the state and federal levels leaves consumers at risk.